February 19, 2018

Biohit GastroPanel finds Korean distributer

GastroPanel diagnoses Helicobacter pylori infection and atrophic gastritis, the two prime risk factors of gastric cancer.
GastroPanel diagnoses Helicobacter pylori infection and atrophic gastritis, the two prime risk factors of gastric cancer.
Istock.com/wickedpix

Finnish biotechology company Biohit and Dow BioMedica have signed an agreement for the distribution of Biohit GastroPanel in Korea.

According to BioMedica, Korea has a high incidence of Helicobacter pylori infection caused atrophic gastritis, and related risks such as gastric cancer.

“GastroPanel as a primary examination will find patients for further examination, and allows more cost-effective utilisation of the scarce endoscopy resources due to the reduction of unnecessary gastroscopies,” states company CEO Young Gill Shin.

The contract is valid for four years with a continuation option. Registration will commence during Q1 2018.

“GastroPanel has proven its suitability and efficacy as the first-line diagnostic test in numerous countries including China, which shares similar dyspepsia and stomach cancer incidence rates as Korea,” adds Biohit CEO Semi Korpela.

Share: